Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Status:
Unknown status
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
Postprandial hyperinsulinemic hypoglycemia is a well-known and potentially severe
complication of Roux-en-Y gastric bypass (RYGB), and the treatment options are limited.
Pasireotide has shown to be effective in preventing hypoglycemia in RYGB operated subjects,
however treatment often leads to increased hyperglycemia.
The purpose of this study is to investigate two doses of pasireotide that are lower than
doses previously used in RYGB operated subjects with postprandial hyperinsulinemic
hypoglycemia.